tiotropium + placebo

Tiotropium + placebo refers to a specific treatment arm used in clinical trials, notably a crossover study by Boehringer Ingelheim (Trial 205.247), where patients with chronic obstructive pulmonary disease (COPD) receive maintenance therapy with tiotropium bromide followed by a placebo dose instead of an active bronchodilator add-on. Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) that provides prolonged bronchodilation by blocking M3 muscarinic receptors in the bronchial smooth muscle. In this trial design, the placebo component serves as a control to evaluate the acute bronchodilator effects of adding short-acting agents, such as ipratropium or fenoterol, to a steady-state tiotropium regimen. Tiotropium is typically delivered via inhalation devices like the HandiHaler or Respimat.

Other names

tiotropium bromide + placebo